Association of insulin pump therapy with raised serum amyloid A in type I diabetes mellitus.
Serum concentrations of serum amyloid A protein, the high-density-lipoprotein-associated tissue amyloid A precursor, were determined in 29 diabetic patients receiving insulin by subcutaneous injection and in 50 receiving subcutaneous infusion pump therapy. Insulin delivered by continuous subcutaneous pumps stimulated serum amyloid A production to levels nearly six times those in normal subjects, nearly twice as much as insulin given by subcutaneous injection. 85% of patients with serum amyloid A levels greater than or equal to 10(4) ng/ml were being treated with insulin pump therapy. The relation between insulin aggregation and amyloid A in diabetes was evaluated in 1 patient; treatment with syringe-aggregated insulin resulted in a nearly 300% increase in serum amyloid A levels. The use of high-potency non-aggregating insulins in the pump treatment of type I diabetic patients may be necessary for optimum therapy.
D000293:Adolescent; D000328:Adult; D000682:Amyloid / Q000032:analysis*; D000686:Amyloidosis / Q000097:blood; D011232:Chemical Precipitation; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007332:Insulin Infusion Systems / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D008970:Molecular Weight; D000685:Serum Amyloid A Protein / Q000032:analysis*; D012995:Solubility; D013594:Syringes
D000682:Amyloid; D000685:Serum Amyloid A Protein